Intellia Therapeutics, Inc., a pharmaceutical company based in the United States, specializes in gene editing through Crispr/Cas9 technology. With a Risk Rating Score of 26.9, Intellia poses a medium risk. The company is dedicated to utilizing ESG technology to target genetically defined diseases such as ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has established partnerships with industry leaders like Regeneron and Novartis to advance its innovative gene editing therapies.